Variable parameters:

CS defined as any narrowing of ≥ 50 %
Remove duplicates (for patients with 2 transplants, second transplant data is removed): TRUE
Remove patients younger than 18 years old: TRUE
File imported: CAD Liver Txp Version 6.9.21.xlsx
MI spreadsheet file name: 8.8.21.MI separate file_RAW.csv
Definition of Death or MACE: Death or any Major Adverse Cardiac Event (cardiac arrest, STEMI, NSTEMI, stroke, new onset systolic or diastolic heart failure) within 90 days of liver transplantation

Report

Meta

General information:

Basic information
Metadata and analysis of the file CAD Liver Txp Version 6.9.21.xlsx
Each row represents one patient.

Authors of the dataset:
**

Date of data collection:
August 2009 - August 2020

Location of data collection:
Newark, New Jersey, USA

Number of observations:
410

Number of variables:
141

OR Plots

CA and CS

Table 1 Coronary angiography and coronary stenosis

Characteristic Total cohort CA Cohort
Overall, N = 4101 CA, N = 1331 no CA, N = 2771 p-value2 Overall, N = 1331 CS, N = 491 no CS, N = 841 p-value2
Age, years 57 (50, 62) 61 (56, 65) 55 (48, 60) <0.001 61 (56, 65) 62 (59, 65) 60 (55, 65) 0.2
Male 269 (66%) 96 (72%) 173 (62%) 0.052 96 (72%) 36 (73%) 60 (71%) 0.8
Ethnicity 0.8 0.7
Caucasian 190 (46%) 67 (50%) 123 (44%) 67 (50%) 22 (45%) 45 (54%)
Hispanic 116 (28%) 34 (26%) 82 (30%) 34 (26%) 14 (29%) 20 (24%)
African American 60 (15%) 19 (14%) 41 (15%) 19 (14%) 7 (14%) 12 (14%)
Asian 41 (10%) 12 (9.0%) 29 (10%) 12 (9.0%) 5 (10%) 7 (8.3%)
Middle Eastern 3 (0.7%) 1 (0.8%) 2 (0.7%) 1 (0.8%) 1 (2.0%) 0 (0%)
Family history of CAD 125 (30%) 52 (39%) 73 (26%) 0.009 52 (39%) 21 (43%) 31 (37%) 0.5
Smoking history 207 (51%) 75 (56%) 132 (48%) 0.10 75 (56%) 29 (59%) 46 (55%) 0.6
Hypertension 204 (50%) 83 (62%) 121 (44%) <0.001 83 (62%) 37 (76%) 46 (55%) 0.017
Hyperlipidemia 62 (15%) 27 (20%) 35 (13%) 0.043 27 (20%) 13 (27%) 14 (17%) 0.2
Diabetes mellitus 142 (35%) 71 (53%) 71 (26%) <0.001 71 (53%) 31 (63%) 40 (48%) 0.081
Chronic kidney disease 95 (23%) 31 (23%) 64 (23%) >0.9 31 (23%) 10 (20%) 21 (25%) 0.5
Connective tissue disease 12 (2.9%) 3 (2.3%) 9 (3.2%) 0.8 3 (2.3%) 1 (2.0%) 2 (2.4%) >0.9
COPD 15 (3.7%) 9 (6.8%) 6 (2.2%) 0.026 9 (6.8%) 4 (8.2%) 5 (6.0%) 0.7
Prior myocardial infarction 5 (1.2%) 4 (3.0%) 1 (0.4%) 0.040 4 (3.0%) 3 (6.1%) 1 (1.2%) 0.14
Prior coronary artery disease 9 (2.2%) 8 (6.0%) 1 (0.4%) <0.001 8 (6.0%) 6 (12%) 2 (2.4%) 0.051
Stroke 6 (1.5%) 3 (2.3%) 3 (1.1%) 0.4 3 (2.3%) 1 (2.0%) 2 (2.4%) >0.9
HIV 4 (1.0%) 1 (0.8%) 3 (1.1%) >0.9 1 (0.8%) 0 (0%) 1 (1.2%) >0.9
Cancer history 13 (3.2%) 5 (3.8%) 8 (2.9%) 0.8 5 (3.8%) 2 (4.1%) 3 (3.6%) >0.9
Alcohol 125 (30%) 43 (32%) 82 (30%) 0.6 43 (32%) 11 (22%) 32 (38%) 0.063
NASH 52 (13%) 27 (20%) 25 (9.0%) 0.001 27 (20%) 14 (29%) 13 (15%) 0.070
Hepatitis B 33 (8.0%) 7 (5.3%) 26 (9.4%) 0.2 7 (5.3%) 2 (4.1%) 5 (6.0%) >0.9
Hepatitis C 167 (41%) 55 (41%) 112 (40%) 0.9 55 (41%) 18 (37%) 37 (44%) 0.4
Hepatocellular carcinoma 155 (38%) 58 (44%) 97 (35%) 0.093 58 (44%) 23 (47%) 35 (42%) 0.6
Autoimmune hepatitis 32 (7.8%) 9 (6.8%) 23 (8.3%) 0.6 9 (6.8%) 2 (4.1%) 7 (8.3%) 0.5
Cryptogenic 34 (8.3%) 12 (9.0%) 22 (7.9%) 0.7 12 (9.0%) 7 (14%) 5 (6.0%) 0.12
Hepatobiliary disease 26 (6.3%) 4 (3.0%) 22 (7.9%) 0.055 4 (3.0%) 0 (0%) 4 (4.8%) 0.3
Ascities 341 (83%) 114 (86%) 227 (82%) 0.3 114 (86%) 42 (86%) 72 (86%) >0.9
Esophageal varices 243 (59%) 84 (63%) 159 (57%) 0.3 84 (63%) 36 (73%) 48 (57%) 0.060
Hepatic encephalopathy 241 (59%) 77 (58%) 164 (59%) 0.8 77 (58%) 28 (57%) 49 (58%) 0.9
Gastrointestinal bleed 115 (28%) 46 (35%) 69 (25%) 0.041 46 (35%) 18 (37%) 28 (33%) 0.7
SBP 57 (14%) 17 (13%) 40 (14%) 0.6 17 (13%) 7 (14%) 10 (12%) 0.7
Prior TIPS 52 (13%) 24 (18%) 28 (10%) 0.024 24 (18%) 10 (20%) 14 (17%) 0.6
Coronary stenosis on catheterization 49 (12%) 49 (37%) 0 (0%) <0.001
Intervention 9 (6.8%) 9 (6.8%) 0 (NA%) >0.9 9 (6.8%) 9 (18%) 0 (0%) <0.001
Positive non-invasive stress test 39 (9.8%) 39 (29%) 0 (0%) <0.001 39 (29%) 14 (29%) 25 (30%) 0.9
CV complications post OLT - MACE 27 (6.6%) 6 (4.5%) 21 (7.6%) 0.2 6 (4.5%) 5 (10%) 1 (1.2%) 0.025
Mortality only 9 (2.2%) 2 (1.5%) 7 (2.5%) 0.7 2 (1.5%) 1 (2.0%) 1 (1.2%) >0.9
Mortality or MACE 28 (6.8%) 6 (4.5%) 22 (7.9%) 0.2 6 (4.5%) 5 (10%) 1 (1.2%) 0.025
MELD-Na score at transplant 23 (19, 29) 23 (19, 27) 24 (19, 30) 0.079 23 (19, 27) 23 (20, 27) 23 (18, 27) 0.5
Coronary catheterization 133 (100%) 49 (100%) 84 (100%) >0.9
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

MM in CS

T2 Mortality or MACE in coronary stenosis

Characteristic Overall, N = 491 Mortality or MACE, N = 51 No mortality or MACE, N = 441 p-value2
Age, years 62 (59, 65) 64 (57, 65) 62 (59, 64) >0.9
Male 36 (73%) 3 (60%) 33 (75%) 0.6
Ethnicity >0.9
African American 7 (14%) 1 (20%) 6 (14%)
Asian 5 (10%) 0 (0%) 5 (11%)
Caucasian 22 (45%) 2 (40%) 20 (45%)
Hispanic 14 (29%) 2 (40%) 12 (27%)
Middle Eastern 1 (2.0%) 0 (0%) 1 (2.3%)
Family history of CAD 21 (43%) 2 (40%) 19 (43%) >0.9
Smoking history 29 (59%) 4 (80%) 25 (57%) 0.6
Hypertension 37 (76%) 4 (80%) 33 (75%) >0.9
Hyperlipidemia 13 (27%) 0 (0%) 13 (30%) 0.3
Diabetes mellitus 31 (63%) 4 (80%) 27 (61%) 0.6
Chronic kidney disease 10 (20%) 1 (20%) 9 (20%) >0.9
Connective tissue disease 1 (2.0%) 0 (0%) 1 (2.3%) >0.9
COPD 4 (8.2%) 1 (20%) 3 (6.8%) 0.4
Prior myocardial infarction 3 (6.1%) 0 (0%) 3 (6.8%) >0.9
Prior coronary artery disease 6 (12%) 0 (0%) 6 (14%) >0.9
Stroke 1 (2.0%) 0 (0%) 1 (2.3%) >0.9
HIV 0 (0%) 0 (0%) 0 (0%) >0.9
Cancer history 2 (4.1%) 1 (20%) 1 (2.3%) 0.2
Alcohol 11 (22%) 1 (20%) 10 (23%) >0.9
NASH 14 (29%) 0 (0%) 14 (32%) 0.3
Hepatitis B 2 (4.1%) 1 (20%) 1 (2.3%) 0.2
Hepatitis C 18 (37%) 4 (80%) 14 (32%) 0.054
Hepatocellular carcinoma 23 (47%) 3 (60%) 20 (45%) 0.7
Autoimmune hepatitis 2 (4.1%) 0 (0%) 2 (4.5%) >0.9
Cryptogenic 7 (14%) 0 (0%) 7 (16%) >0.9
Hepatobiliary disease 0 (0%) 0 (0%) 0 (0%) >0.9
Ascities 42 (86%) 5 (100%) 37 (84%) >0.9
Esophageal varices 36 (73%) 2 (40%) 34 (77%) 0.11
Hepatic encephalopathy 28 (57%) 3 (60%) 25 (57%) >0.9
Gastrointestinal bleed 18 (37%) 2 (40%) 16 (36%) >0.9
SBP 7 (14%) 2 (40%) 5 (11%) 0.14
Prior TIPS 10 (20%) 0 (0%) 10 (23%) 0.6
Intervention and CS 0 (0%) 0 (0%) 0 (0%) 0.6
Coronary catheterization 49 (100%) 5 (100%) 44 (100%) >0.9
Coronary stenosis on catheterization 49 (100%) 5 (100%) 44 (100%) >0.9
Intervention 9 (18%) 0 (0%) 9 (20%) 0.6
Positive non-invasive stress test 14 (29%) 1 (20%) 13 (30%) >0.9
CV complications post OLT - MACE 5 (10%) 5 (100%) 0 (0%) <0.001
Mortality only 1 (2.0%) 1 (20%) 0 (0%) 0.10
1 Median (IQR); n (%)
2 Wilcoxon rank sum exact test; Fisher's exact test

Complic.

T3 Complications within 90 days of OLT in coronary angiography

Characteristic Overall, N = 4101 CA, N = 1331 no CA, N = 2771 p-value2
MELD-Na score at transplant 23 (19, 29) 23 (19, 27) 24 (19, 30) 0.079
Liver complication post cath - overall 3 (2.3%) 3 (2.3%) 0 (NA%) >0.9
Liver complication post cath - variceal bleeding 1 (0.8%) 1 (0.8%) 0 (NA%) >0.9
Liver complication post cath - GI bleed 4 (3.0%) 4 (3.0%) 0 (NA%) >0.9
Liver complication post cath- Other bleed / hematoma 6 (4.5%) 6 (4.5%) 0 (NA%) >0.9
Liver complication post cath - HE 23 (17%) 23 (17%) 0 (NA%)
Liver complication post cath - SBP 3 (2.3%) 3 (2.3%) 0 (NA%) >0.9
Liver complication post transplant - overall 89 (22%) 29 (22%) 60 (22%) >0.9
Liver complication post transplant - variceal bleeding 1 (0.2%) 0 (0%) 1 (0.4%) >0.9
Liver complication post transplant - GI bleed 16 (3.9%) 6 (4.5%) 10 (3.6%) 0.7
Liver complication post transplant - Other bleed / hematoma 48 (12%) 16 (12%) 32 (12%) 0.9
Liver complication post transplant - HE 7 (1.7%) 3 (2.3%) 4 (1.4%) 0.7
Liver complication post transplant - SBP 7 (1.7%) 1 (0.8%) 6 (2.2%) 0.4
CV complications post cath - MACE 0 (0%) 0 (0%) 0 (NA%)
CV complications post cath - card arrest 0 (0%) 0 (0%) 0 (NA%)
CV complications post cath - HF 0 (0%) 0 (0%) 0 (NA%)
CV complications post cath - MI 0 (0%) 0 (0%) 0 (NA%)
CV complications post cath - Afib 3 (2.3%) 3 (2.3%) 0 (NA%) >0.9
CV complications post cath - PE 1 (0.8%) 1 (0.8%) 0 (NA%) >0.9
CV complications post cath - stroke 0 (0%) 0 (0%) 0 (NA%)
CV complications post OLT - MACE 27 (6.6%) 6 (4.5%) 21 (7.6%) 0.2
CV complications post OLT - Card arrest 12 (2.9%) 2 (1.5%) 10 (3.6%) 0.4
CV complications post OLT - HF 14 (3.4%) 3 (2.3%) 11 (4.0%) 0.6
CV complications post OLT - MI 3 (0.7%) 1 (0.8%) 2 (0.7%) >0.9
CV complications post OLT - Afib 32 (7.8%) 14 (11%) 18 (6.5%) 0.2
CV complications post OLT - PE 3 (0.7%) 2 (1.5%) 1 (0.4%) 0.2
CV complications post OLT - Pericad eff 1 (0.2%) 0 (0%) 1 (0.4%) >0.9
CV complications post OLT - tamponade 0 (0%) 0 (0%) 0 (0%)
CV complications post OLT - Stroke 1 (0.2%) 0 (0%) 1 (0.4%) >0.9
Typer 1 MI 1 (0.2%) 0 (0%) 1 (0.4%) >0.9
Typer 2 MI 2 (0.5%) 1 (0.8%) 1 (0.4%) 0.5
Mortality only 9 (2.2%) 2 (1.5%) 7 (2.5%) 0.7
Mortality or MACE 28 (6.8%) 6 (4.5%) 22 (7.9%) 0.2
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test

NST

T4 Non-invasive stress test results in those with and without coronary stenosis

Characteristic Overall, N = 1331 negative NST and negative NARROWING, N = 591 negative NST and positive NARROWING, N = 351 positive NST and negative NARROWING, N = 251 positivs NST and positive NARROWING, N = 141 p-value2
Age, years 61 (56, 65) 61 (55, 66) 62 (59, 64) 57 (54, 61) 62 (56, 66) 0.091
Male >0.9
Female 37 (28%) 16 (27%) 9 (26%) 8 (32%) 4 (29%)
Male 96 (72%) 43 (73%) 26 (74%) 17 (68%) 10 (71%)
Ethnicity
African American 19 (14%) 10 (17%) 6 (17%) 2 (8.0%) 1 (7.1%)
Asian 12 (9.0%) 5 (8.5%) 4 (11%) 2 (8.0%) 1 (7.1%)
Caucasian 67 (50%) 32 (54%) 15 (43%) 13 (52%) 7 (50%)
Hispanic 34 (26%) 12 (20%) 10 (29%) 8 (32%) 4 (29%)
Middle Eastern 1 (0.8%) 0 (0%) 0 (0%) 0 (0%) 1 (7.1%)
Family history of CAD 52 (39%) 21 (36%) 12 (34%) 10 (40%) 9 (64%) 0.2
Smoking history 75 (56%) 35 (59%) 19 (54%) 11 (44%) 10 (71%) 0.4
Hypertension 83 (62%) 33 (56%) 28 (80%) 13 (52%) 9 (64%) 0.077
Hyperlipidemia 27 (20%) 9 (15%) 10 (29%) 5 (20%) 3 (21%) 0.5
Diabetes mellitus 71 (53%) 28 (47%) 22 (63%) 12 (48%) 9 (64%) 0.4
Chronic kidney disease 31 (23%) 16 (27%) 6 (17%) 5 (20%) 4 (29%) 0.7
Connective tissue disease 3 (2.3%) 2 (3.4%) 1 (2.9%) 0 (0%) 0 (0%) >0.9
COPD 9 (6.8%) 4 (6.8%) 3 (8.6%) 1 (4.0%) 1 (7.1%) >0.9
Prior myocardial infarction 4 (3.0%) 1 (1.7%) 2 (5.7%) 0 (0%) 1 (7.1%) 0.3
Prior coronary artery disease 8 (6.0%) 0 (0%) 4 (11%) 2 (8.0%) 2 (14%) 0.013
Stroke 3 (2.3%) 2 (3.4%) 0 (0%) 0 (0%) 1 (7.1%) 0.3
HIV 1 (0.8%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) >0.9
Cancer history 5 (3.8%) 2 (3.4%) 1 (2.9%) 1 (4.0%) 1 (7.1%) 0.8
Alcohol 43 (32%) 19 (32%) 9 (26%) 13 (52%) 2 (14%) 0.076
NASH 27 (20%) 11 (19%) 12 (34%) 2 (8.0%) 2 (14%) 0.086
Hepatitis B 7 (5.3%) 4 (6.8%) 2 (5.7%) 1 (4.0%) 0 (0%) >0.9
Hepatitis C 55 (41%) 29 (49%) 11 (31%) 8 (32%) 7 (50%) 0.2
Hepatocellular carcinoma 58 (44%) 25 (42%) 19 (54%) 10 (40%) 4 (29%) 0.4
Autoimmune hepatitis 9 (6.8%) 3 (5.1%) 2 (5.7%) 4 (16%) 0 (0%) 0.3
Cryptogenic 12 (9.0%) 4 (6.8%) 4 (11%) 1 (4.0%) 3 (21%) 0.3
Hepatobiliary disease 4 (3.0%) 3 (5.1%) 0 (0%) 1 (4.0%) 0 (0%) 0.6
Ascities 114 (86%) 50 (85%) 29 (83%) 22 (88%) 13 (93%) >0.9
Esophageal varices 84 (63%) 28 (47%) 25 (71%) 20 (80%) 11 (79%) 0.008
Hepatic encephalopathy 77 (58%) 31 (53%) 20 (57%) 18 (72%) 8 (57%) 0.4
Gastrointestinal bleed 46 (35%) 19 (32%) 11 (31%) 9 (36%) 7 (50%) 0.6
SBP 17 (13%) 5 (8.5%) 5 (14%) 5 (20%) 2 (14%) 0.5
Prior TIPS 24 (18%) 9 (15%) 6 (17%) 5 (20%) 4 (29%) 0.7
Intervention and CS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) <0.001
Coronary catheterization 133 (100%) 59 (100%) 35 (100%) 25 (100%) 14 (100%) >0.9
Coronary stenosis on catheterization 49 (37%) 0 (0%) 35 (100%) 0 (0%) 14 (100%) <0.001
Intervention 9 (6.8%) 0 (0%) 7 (20%) 0 (0%) 2 (14%) <0.001
Positive non-invasive stress test 39 (29%) 0 (0%) 0 (0%) 25 (100%) 14 (100%) <0.001
CV complications post OLT - MACE 6 (4.5%) 1 (1.7%) 4 (11%) 0 (0%) 1 (7.1%) 0.072
Mortality only 2 (1.5%) 1 (1.7%) 1 (2.9%) 0 (0%) 0 (0%) >0.9
Mortality or MACE 6 (4.5%) 1 (1.7%) 4 (11%) 0 (0%) 1 (7.1%) 0.072
1 Median (IQR); n (%)
2 Kruskal-Wallis rank sum test; Fisher's exact test; Pearson's Chi-squared test

Comparison within groups 1

Characteristic Overall, N = 941 negative NST and negative NARROWING, N = 591 negative NST and positive NARROWING, N = 351 p-value2
Age, years 61 (57, 65) 61 (55, 66) 62 (59, 64) 0.8
Male 0.9
Female 25 (27%) 16 (27%) 9 (26%)
Male 69 (73%) 43 (73%) 26 (74%)
Ethnicity 0.7
African American 16 (17%) 10 (17%) 6 (17%)
Asian 9 (9.6%) 5 (8.5%) 4 (11%)
Caucasian 47 (50%) 32 (54%) 15 (43%)
Hispanic 22 (23%) 12 (20%) 10 (29%)
Middle Eastern 0 (0%) 0 (0%) 0 (0%)
Family history of CAD 33 (35%) 21 (36%) 12 (34%) 0.9
Smoking history 54 (57%) 35 (59%) 19 (54%) 0.6
Hypertension 61 (65%) 33 (56%) 28 (80%) 0.018
Hyperlipidemia 19 (20%) 9 (15%) 10 (29%) 0.12
Diabetes mellitus 50 (53%) 28 (47%) 22 (63%) 0.15
Chronic kidney disease 22 (23%) 16 (27%) 6 (17%) 0.3
Connective tissue disease 3 (3.2%) 2 (3.4%) 1 (2.9%) >0.9
COPD 7 (7.4%) 4 (6.8%) 3 (8.6%) >0.9
Prior myocardial infarction 3 (3.2%) 1 (1.7%) 2 (5.7%) 0.6
Prior coronary artery disease 4 (4.3%) 0 (0%) 4 (11%) 0.017
Stroke 2 (2.1%) 2 (3.4%) 0 (0%) 0.5
HIV 1 (1.1%) 1 (1.7%) 0 (0%) >0.9
Cancer history 3 (3.2%) 2 (3.4%) 1 (2.9%) >0.9
Alcohol 28 (30%) 19 (32%) 9 (26%) 0.5
NASH 23 (24%) 11 (19%) 12 (34%) 0.088
Hepatitis B 6 (6.4%) 4 (6.8%) 2 (5.7%) >0.9
Hepatitis C 40 (43%) 29 (49%) 11 (31%) 0.093
Hepatocellular carcinoma 44 (47%) 25 (42%) 19 (54%) 0.3
Autoimmune hepatitis 5 (5.3%) 3 (5.1%) 2 (5.7%) >0.9
Cryptogenic 8 (8.5%) 4 (6.8%) 4 (11%) 0.5
Hepatobiliary disease 3 (3.2%) 3 (5.1%) 0 (0%) 0.3
Ascities 79 (84%) 50 (85%) 29 (83%) 0.8
Esophageal varices 53 (56%) 28 (47%) 25 (71%) 0.023
Hepatic encephalopathy 51 (54%) 31 (53%) 20 (57%) 0.7
Gastrointestinal bleed 30 (32%) 19 (32%) 11 (31%) >0.9
SBP 10 (11%) 5 (8.5%) 5 (14%) 0.5
Prior TIPS 15 (16%) 9 (15%) 6 (17%) 0.8
Intervention and CS 0 (0%) 0 (0%) 0 (0%) <0.001
Coronary catheterization 94 (100%) 59 (100%) 35 (100%) >0.9
Coronary stenosis on catheterization 35 (37%) 0 (0%) 35 (100%) <0.001
Intervention 7 (7.4%) 0 (0%) 7 (20%) <0.001
Positive non-invasive stress test 0 (0%) 0 (0%) 0 (0%) >0.9
CV complications post OLT - MACE 5 (5.3%) 1 (1.7%) 4 (11%) 0.062
Mortality only 2 (2.1%) 1 (1.7%) 1 (2.9%) >0.9
Mortality or MACE 5 (5.3%) 1 (1.7%) 4 (11%) 0.062
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

Comparison within groups 2

Characteristic Overall, N = 391 positive NST and negative NARROWING, N = 251 positivs NST and positive NARROWING, N = 141 p-value2
Age, years 59 (54, 62) 57 (54, 61) 62 (56, 66) 0.11
Male >0.9
Female 12 (31%) 8 (32%) 4 (29%)
Male 27 (69%) 17 (68%) 10 (71%)
Ethnicity >0.9
African American 3 (7.7%) 2 (8.0%) 1 (7.1%)
Asian 3 (7.7%) 2 (8.0%) 1 (7.1%)
Caucasian 20 (51%) 13 (52%) 7 (50%)
Hispanic 12 (31%) 8 (32%) 4 (29%)
Middle Eastern 1 (2.6%) 0 (0%) 1 (7.1%)
Family history of CAD 19 (49%) 10 (40%) 9 (64%) 0.15
Smoking history 21 (54%) 11 (44%) 10 (71%) 0.10
Hypertension 22 (56%) 13 (52%) 9 (64%) 0.5
Hyperlipidemia 8 (21%) 5 (20%) 3 (21%) >0.9
Diabetes mellitus 21 (54%) 12 (48%) 9 (64%) 0.3
Chronic kidney disease 9 (23%) 5 (20%) 4 (29%) 0.7
Connective tissue disease 0 (0%) 0 (0%) 0 (0%) >0.9
COPD 2 (5.1%) 1 (4.0%) 1 (7.1%) >0.9
Prior myocardial infarction 1 (2.6%) 0 (0%) 1 (7.1%) 0.4
Prior coronary artery disease 4 (10%) 2 (8.0%) 2 (14%) 0.6
Stroke 1 (2.6%) 0 (0%) 1 (7.1%) 0.4
HIV 0 (0%) 0 (0%) 0 (0%) >0.9
Cancer history 2 (5.1%) 1 (4.0%) 1 (7.1%) >0.9
Alcohol 15 (38%) 13 (52%) 2 (14%) 0.020
NASH 4 (10%) 2 (8.0%) 2 (14%) 0.6
Hepatitis B 1 (2.6%) 1 (4.0%) 0 (0%) >0.9
Hepatitis C 15 (38%) 8 (32%) 7 (50%) 0.3
Hepatocellular carcinoma 14 (36%) 10 (40%) 4 (29%) 0.5
Autoimmune hepatitis 4 (10%) 4 (16%) 0 (0%) 0.3
Cryptogenic 4 (10%) 1 (4.0%) 3 (21%) 0.12
Hepatobiliary disease 1 (2.6%) 1 (4.0%) 0 (0%) >0.9
Ascities 35 (90%) 22 (88%) 13 (93%) >0.9
Esophageal varices 31 (79%) 20 (80%) 11 (79%) >0.9
Hepatic encephalopathy 26 (67%) 18 (72%) 8 (57%) 0.5
Gastrointestinal bleed 16 (41%) 9 (36%) 7 (50%) 0.4
SBP 7 (18%) 5 (20%) 2 (14%) >0.9
Prior TIPS 9 (23%) 5 (20%) 4 (29%) 0.7
Intervention and CS 0 (0%) 0 (0%) 0 (0%) <0.001
Coronary catheterization 39 (100%) 25 (100%) 14 (100%) >0.9
Coronary stenosis on catheterization 14 (36%) 0 (0%) 14 (100%) <0.001
Intervention 2 (5.1%) 0 (0%) 2 (14%) 0.12
Positive non-invasive stress test 39 (100%) 25 (100%) 14 (100%) >0.9
CV complications post OLT - MACE 1 (2.6%) 0 (0%) 1 (7.1%) 0.4
Mortality only 0 (0%) 0 (0%) 0 (0%) >0.9
Mortality or MACE 1 (2.6%) 0 (0%) 1 (7.1%) 0.4
1 Median (IQR); n (%)
2 Wilcoxon rank sum exact test; Fisher's exact test; Pearson's Chi-squared test

PCI

T5 Coronary angiography data with respect to mortality or MACE

Characteristic Overall, N = 1331 Mortality or MACE, N = 61 No mortality or MACE, N = 1271 p-value2
Femoral access 105 (79%) 4 (67%) 101 (80%) 0.6
Radial access 28 (21%) 2 (33%) 26 (20%) 0.6
Left main stenosis, % 3 (13) 3 (8) 3 (13) 0.4
Proximal LAD stenosis, % 10 (25) 12 (20) 10 (25) 0.4
Mid to distal LAD stenosis, % 13 (26) 17 (26) 13 (26) 0.6
Left circumflex stenosis, % 12 (27) 13 (22) 12 (28) 0.5
RCA stenosis, % 10 (22) 17 (27) 9 (21) 0.4
Ramus stenosis, % 1.1 (9.2) 0.0 (0.0) 1.2 (9.4) 0.8
Other, stenosis % 1.3 (9.6) 0.0 (0.0) 1.4 (9.8) 0.7
PCI 8 (6.0%) 0 (0%) 8 (6.3%) >0.9
POBA 1 (0.8%) 0 (0%) 1 (0.8%) >0.9
CABG 1 (0.8%) 0 (0%) 1 (0.8%) >0.9
DES 0 (0%) 0 (0%) 0 (0%)
BMS 7 (5.3%) 0 (0%) 7 (5.5%) >0.9
Left main stenosis present 4 (3.0%) 0 (0%) 4 (3.1%) >0.9
Proximal LAD stenosis present 15 (11%) 1 (17%) 14 (11%) 0.5
Mid to distal LAD stenosis present 23 (17%) 2 (33%) 21 (17%) 0.3
Left circumflex stenosis present 18 (14%) 1 (17%) 17 (13%) 0.6
RCA stenosis present 12 (9.0%) 1 (17%) 11 (8.7%) 0.4
Ramus stenosis present 2 (1.5%) 0 (0%) 2 (1.6%) >0.9
Other stenosis present 5 (3.8%) 0 (0%) 5 (3.9%) >0.9
Any LAD stenosis present 32 (24%) 3 (50%) 29 (23%) 0.2
Number of vessels with stenosis 0.044
1 84 (63%) 1 (17%) 83 (65%)
2 33 (25%) 5 (83%) 28 (22%)
3 10 (7.5%) 0 (0%) 10 (7.9%)
4 4 (3.0%) 0 (0%) 4 (3.1%)
5 2 (1.5%) 0 (0%) 2 (1.6%)
1 n (%); Mean (SD)
2 Fisher's exact test; Wilcoxon rank sum test

T5A Coronary angiography only in patients with Coronary Stenosis (CS)

Characteristic Overall, N = 491 Mortality or MACE, N = 51 No mortality or MACE, N = 441 p-value2
Femoral access 39 (80%) 3 (60%) 36 (82%) 0.3
Radial access 10 (20%) 2 (40%) 8 (18%) 0.3
Left main stenosis, % 7 (20) 4 (9) 7 (21) 0.7
Proximal LAD stenosis, % 23 (36) 10 (22) 25 (37) 0.4
Mid to distal LAD stenosis, % 31 (34) 20 (27) 32 (35) 0.5
Left circumflex stenosis, % 30 (38) 16 (23) 31 (39) 0.5
RCA stenosis, % 21 (30) 12 (27) 22 (31) 0.4
Ramus stenosis, % 3.1 (15.0) 0.0 (0.0) 3.4 (15.8) 0.7
Other, stenosis % 1.6 (8.3) 0.0 (0.0) 1.8 (8.7) 0.7
PCI 8 (16%) 0 (0%) 8 (18%) 0.6
POBA 1 (2.0%) 0 (0%) 1 (2.3%) >0.9
CABG 1 (2.0%) 0 (0%) 1 (2.3%) >0.9
DES 0 (0%) 0 (0%) 0 (0%)
BMS 7 (14%) 0 (0%) 7 (16%) >0.9
Left main stenosis present 4 (8.2%) 0 (0%) 4 (9.1%) >0.9
Proximal LAD stenosis present 15 (31%) 1 (20%) 14 (32%) >0.9
Mid to distal LAD stenosis present 23 (47%) 2 (40%) 21 (48%) >0.9
Left circumflex stenosis present 18 (37%) 1 (20%) 17 (39%) 0.6
RCA stenosis present 12 (24%) 1 (20%) 11 (25%) >0.9
Ramus stenosis present 2 (4.1%) 0 (0%) 2 (4.5%) >0.9
Other stenosis present 5 (10%) 0 (0%) 5 (11%) >0.9
Any LAD stenosis present 32 (65%) 3 (60%) 29 (66%) >0.9
Number of vessels with stenosis 0.7
2 33 (67%) 5 (100%) 28 (64%)
3 10 (20%) 0 (0%) 10 (23%)
4 4 (8.2%) 0 (0%) 4 (9.1%)
5 2 (4.1%) 0 (0%) 2 (4.5%)
1 n (%); Mean (SD)
2 Fisher's exact test; Wilcoxon rank sum test

Inteventions

T6 Interventions

Characteristic CS cohort CA Cohort
Overall, N = 491 Intervention, N = 91 No intervention, N = 401 p-value2 Overall, N = 1331 CS with intervention, N = 91 CS with no intervention, N = 401 No CS, N = 841 p-value3
dividing_variable >0.9 <0.001
negative NST and positive NARROWING 35 (71%) 7 (78%) 28 (70%) 35 (26%) 7 (78%) 28 (70%) 0 (0%)
positivs NST and positive NARROWING 14 (29%) 2 (22%) 12 (30%) 14 (11%) 2 (22%) 12 (30%) 0 (0%)
negative NST and negative NARROWING 0 (0%) 0 (0%) 0 (0%) 59 (44%) 0 (0%) 0 (0%) 59 (70%)
positive NST and negative NARROWING 0 (0%) 0 (0%) 0 (0%) 25 (19%) 0 (0%) 0 (0%) 25 (30%)
Age, years 62 (59, 65) 62 (61, 62) 62 (58, 65) 0.8 61 (56, 65) 62 (61, 62) 62 (58, 65) 60 (55, 65) 0.5
Male 36 (73%) 8 (89%) 28 (70%) 0.4 96 (72%) 8 (89%) 28 (70%) 60 (71%) 0.6
Ethnicity >0.9 0.8
Caucasian 22 (45%) 5 (56%) 17 (42%) 67 (50%) 5 (56%) 17 (42%) 45 (54%)
Hispanic 14 (29%) 2 (22%) 12 (30%) 34 (26%) 2 (22%) 12 (30%) 20 (24%)
African American 7 (14%) 1 (11%) 6 (15%) 19 (14%) 1 (11%) 6 (15%) 12 (14%)
Asian 5 (10%) 1 (11%) 4 (10%) 12 (9.0%) 1 (11%) 4 (10%) 7 (8.3%)
Middle Eastern 1 (2.0%) 0 (0%) 1 (2.5%) 1 (0.8%) 0 (0%) 1 (2.5%) 0 (0%)
Family history of CAD 21 (43%) 3 (33%) 18 (45%) 0.7 52 (39%) 3 (33%) 18 (45%) 31 (37%) 0.7
Smoking history 29 (59%) 7 (78%) 22 (55%) 0.3 75 (56%) 7 (78%) 22 (55%) 46 (55%) 0.5
Hypertension 37 (76%) 7 (78%) 30 (75%) >0.9 83 (62%) 7 (78%) 30 (75%) 46 (55%) 0.065
Hyperlipidemia 13 (27%) 4 (44%) 9 (22%) 0.2 27 (20%) 4 (44%) 9 (22%) 14 (17%) 0.12
Diabetes mellitus 31 (63%) 7 (78%) 24 (60%) 0.5 71 (53%) 7 (78%) 24 (60%) 40 (48%) 0.2
Chronic kidney disease 10 (20%) 2 (22%) 8 (20%) >0.9 31 (23%) 2 (22%) 8 (20%) 21 (25%) 0.9
Connective tissue disease 1 (2.0%) 0 (0%) 1 (2.5%) >0.9 3 (2.3%) 0 (0%) 1 (2.5%) 2 (2.4%) >0.9
COPD 4 (8.2%) 1 (11%) 3 (7.5%) 0.6 9 (6.8%) 1 (11%) 3 (7.5%) 5 (6.0%) 0.5
Prior myocardial infarction 3 (6.1%) 2 (22%) 1 (2.5%) 0.083 4 (3.0%) 2 (22%) 1 (2.5%) 1 (1.2%) 0.027
Prior coronary artery disease 6 (12%) 3 (33%) 3 (7.5%) 0.067 8 (6.0%) 3 (33%) 3 (7.5%) 2 (2.4%) 0.006
Stroke 1 (2.0%) 0 (0%) 1 (2.5%) >0.9 3 (2.3%) 0 (0%) 1 (2.5%) 2 (2.4%) >0.9
HIV 0 (0%) 0 (0%) 0 (0%) >0.9 1 (0.8%) 0 (0%) 0 (0%) 1 (1.2%) >0.9
Cancer history 2 (4.1%) 0 (0%) 2 (5.0%) >0.9 5 (3.8%) 0 (0%) 2 (5.0%) 3 (3.6%) 0.8
Alcohol 11 (22%) 5 (56%) 6 (15%) 0.019 43 (32%) 5 (56%) 6 (15%) 32 (38%) 0.007
NASH 14 (29%) 2 (22%) 12 (30%) >0.9 27 (20%) 2 (22%) 12 (30%) 13 (15%) 0.2
Hepatitis B 2 (4.1%) 1 (11%) 1 (2.5%) 0.3 7 (5.3%) 1 (11%) 1 (2.5%) 5 (6.0%) 0.4
Hepatitis C 18 (37%) 1 (11%) 17 (42%) 0.13 55 (41%) 1 (11%) 17 (42%) 37 (44%) 0.2
Hepatocellular carcinoma 23 (47%) 4 (44%) 19 (48%) >0.9 58 (44%) 4 (44%) 19 (48%) 35 (42%) 0.8
Autoimmune hepatitis 2 (4.1%) 0 (0%) 2 (5.0%) >0.9 9 (6.8%) 0 (0%) 2 (5.0%) 7 (8.3%) 0.9
Cryptogenic 7 (14%) 2 (22%) 5 (12%) 0.6 12 (9.0%) 2 (22%) 5 (12%) 5 (6.0%) 0.12
Hepatobiliary disease 0 (0%) 0 (0%) 0 (0%) >0.9 4 (3.0%) 0 (0%) 0 (0%) 4 (4.8%) 0.5
Ascities 42 (86%) 7 (78%) 35 (88%) 0.6 114 (86%) 7 (78%) 35 (88%) 72 (86%) 0.8
Esophageal varices 36 (73%) 9 (100%) 27 (68%) 0.089 84 (63%) 9 (100%) 27 (68%) 48 (57%) 0.023
Hepatic encephalopathy 28 (57%) 5 (56%) 23 (57%) >0.9 77 (58%) 5 (56%) 23 (57%) 49 (58%) >0.9
Gastrointestinal bleed 18 (37%) 1 (11%) 17 (42%) 0.13 46 (35%) 1 (11%) 17 (42%) 28 (33%) 0.2
SBP 7 (14%) 1 (11%) 6 (15%) >0.9 17 (13%) 1 (11%) 6 (15%) 10 (12%) >0.9
Prior TIPS 10 (20%) 0 (0%) 10 (25%) 0.2 24 (18%) 0 (0%) 10 (25%) 14 (17%) 0.2
Positive non-invasive stress test 14 (29%) 2 (22%) 12 (30%) >0.9 39 (29%) 2 (22%) 12 (30%) 25 (30%) >0.9
CV complications post OLT - MACE 5 (10%) 0 (0%) 5 (12%) 0.6 6 (4.5%) 0 (0%) 5 (12%) 1 (1.2%) 0.018
Mortality only 1 (2.0%) 0 (0%) 1 (2.5%) >0.9 2 (1.5%) 0 (0%) 1 (2.5%) 1 (1.2%) 0.6
Mortality or MACE 5 (10%) 0 (0%) 5 (12%) 0.6 6 (4.5%) 0 (0%) 5 (12%) 1 (1.2%) 0.018
1 n (%); Median (IQR)
2 Fisher's exact test; Wilcoxon rank sum exact test
3 Fisher's exact test; Kruskal-Wallis rank sum test

Suppl.

S1 Background and demographics with respect to mortality or MACE in those who did not undergo CA

Characteristic Overall, N = 2771 Mortality or MACE, N = 221 No mortality or MACE, N = 2551 p-value2
Age, years 55 (48, 60) 57 (50, 59) 55 (48, 60) 0.6
Male 173 (62%) 11 (50%) 162 (64%) 0.2
Ethnicity >0.9
African American 41 (15%) 2 (9.1%) 39 (15%)
Asian 29 (10%) 2 (9.1%) 27 (11%)
Caucasian 123 (44%) 10 (45%) 113 (44%)
Hispanic 82 (30%) 8 (36%) 74 (29%)
Middle Eastern 2 (0.7%) 0 (0%) 2 (0.8%)
Family history of CAD 73 (26%) 3 (14%) 70 (27%) 0.2
Smoking history 132 (48%) 10 (45%) 122 (48%) 0.8
Hypertension 121 (44%) 9 (41%) 112 (44%) 0.8
Hyperlipidemia 35 (13%) 3 (14%) 32 (13%) 0.7
Diabetes mellitus 71 (26%) 8 (36%) 63 (25%) 0.2
Chronic kidney disease 64 (23%) 6 (27%) 58 (23%) 0.6
Connective tissue disease 9 (3.2%) 0 (0%) 9 (3.5%) >0.9
COPD 6 (2.2%) 0 (0%) 6 (2.4%) >0.9
Prior myocardial infarction 1 (0.4%) 0 (0%) 1 (0.4%) >0.9
Prior coronary artery disease 1 (0.4%) 0 (0%) 1 (0.4%) >0.9
Stroke 3 (1.1%) 0 (0%) 3 (1.2%) >0.9
HIV 3 (1.1%) 0 (0%) 3 (1.2%) >0.9
Cancer history 8 (2.9%) 0 (0%) 8 (3.1%) >0.9
Alcohol 82 (30%) 11 (50%) 71 (28%) 0.029
NASH 25 (9.0%) 4 (18%) 21 (8.2%) 0.12
Hepatitis B 26 (9.4%) 0 (0%) 26 (10%) 0.2
Hepatitis C 112 (40%) 6 (27%) 106 (42%) 0.2
Hepatocellular carcinoma 97 (35%) 4 (18%) 93 (36%) 0.084
Autoimmune hepatitis 23 (8.3%) 1 (4.5%) 22 (8.6%) >0.9
Cryptogenic 22 (7.9%) 3 (14%) 19 (7.5%) 0.4
Hepatobiliary disease 22 (7.9%) 1 (4.5%) 21 (8.2%) >0.9
Ascities 227 (82%) 20 (91%) 207 (81%) 0.4
Esophageal varices 159 (57%) 15 (68%) 144 (56%) 0.3
Hepatic encephalopathy 164 (59%) 18 (82%) 146 (57%) 0.024
Gastrointestinal bleed 69 (25%) 6 (27%) 63 (25%) 0.8
SBP 40 (14%) 5 (23%) 35 (14%) 0.3
Prior TIPS 28 (10%) 0 (0%) 28 (11%) 0.14
CV complications post OLT - MACE 21 (7.6%) 21 (95%) 0 (0%) <0.001
Mortality only 7 (2.5%) 7 (32%) 0 (0%) <0.001
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

S2 Cardiac workup before liver transplant

Characteristic Overall, N = 4101 CA, N = 1331 no CA, N = 2771 p-value2
Positive non-invasive stress test 39 (9.8%) 39 (29%) 0 (0%) <0.001
lvef 65 (65, 74) 65 (62, 70) 65 (65, 75) 0.3
prior_lhc 23 (5.6%) 16 (12%) 7 (2.5%) <0.001
prior_pci 1 (0.8%) 1 (0.8%) 0 (NA%) >0.9
prior_poba 1 (0.8%) 1 (0.8%) 0 (NA%) >0.9
prior_cabg 2 (1.5%) 2 (1.5%) 0 (NA%) >0.9
noac 1 (0.2%) 1 (0.8%) 0 (0%) 0.3
vka 3 (0.7%) 1 (0.8%) 2 (0.7%) >0.9
1 n (%); Median (IQR)
2 Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test

S3 Labs at time of CA

Characteristic N = 1331
MELD Na at transplant 20 (16, 26)
MELD score 19 (14, 25)
Platelets 68 (45, 96)
Hemoglobin 10.70 (9.03, 12.30)
INR 1.70 (1.30, 2.03)
Creatinine 0.90 (0.70, 1.20)
MELD-Na score at transplant 23 (19, 27)
HGB at transplant 9.60 (8.60, 11.20)
1 Median (IQR)

S4 (-)NIST: CA vs. no CA

Characteristic Overall, N = 3591 CA, N = 941 no CA, N = 2651 p-value2
Age, years 57 (50, 62) 61 (57, 65) 55 (48, 60) <0.001
Male 0.078
Female 122 (34%) 25 (27%) 97 (37%)
Male 237 (66%) 69 (73%) 168 (63%)
Ethnicity 0.7
African American 55 (15%) 16 (17%) 39 (15%)
Asian 36 (10%) 9 (9.6%) 27 (10%)
Caucasian 164 (46%) 47 (50%) 117 (44%)
Hispanic 102 (28%) 22 (23%) 80 (30%)
Middle Eastern 2 (0.6%) 0 (0%) 2 (0.8%)
Family history of CAD 103 (29%) 33 (35%) 70 (26%) 0.11
Smoking history 183 (51%) 54 (57%) 129 (49%) 0.2
Hypertension 177 (49%) 61 (65%) 116 (44%) <0.001
Hyperlipidemia 52 (14%) 19 (20%) 33 (12%) 0.066
Diabetes mellitus 121 (34%) 50 (53%) 71 (27%) <0.001
Chronic kidney disease 84 (23%) 22 (23%) 62 (23%) >0.9
Connective tissue disease 12 (3.3%) 3 (3.2%) 9 (3.4%) >0.9
COPD 13 (3.6%) 7 (7.4%) 6 (2.3%) 0.046
Prior myocardial infarction 4 (1.1%) 3 (3.2%) 1 (0.4%) 0.057
Prior coronary artery disease 5 (1.4%) 4 (4.3%) 1 (0.4%) 0.018
Stroke 5 (1.4%) 2 (2.1%) 3 (1.1%) 0.6
HIV 4 (1.1%) 1 (1.1%) 3 (1.1%) >0.9
Cancer history 11 (3.1%) 3 (3.2%) 8 (3.0%) >0.9
Alcohol 108 (30%) 28 (30%) 80 (30%) >0.9
NASH 48 (13%) 23 (24%) 25 (9.4%) <0.001
Hepatitis B 31 (8.6%) 6 (6.4%) 25 (9.4%) 0.4
Hepatitis C 146 (41%) 40 (43%) 106 (40%) 0.7
Hepatocellular carcinoma 137 (38%) 44 (47%) 93 (35%) 0.045
Autoimmune hepatitis 27 (7.5%) 5 (5.3%) 22 (8.3%) 0.3
Cryptogenic 29 (8.1%) 8 (8.5%) 21 (7.9%) 0.9
Hepatobiliary disease 24 (6.7%) 3 (3.2%) 21 (7.9%) 0.11
Ascities 296 (82%) 79 (84%) 217 (82%) 0.6
Esophageal varices 206 (57%) 53 (56%) 153 (58%) 0.8
Hepatic encephalopathy 208 (58%) 51 (54%) 157 (59%) 0.4
Gastrointestinal bleed 97 (27%) 30 (32%) 67 (25%) 0.2
SBP 49 (14%) 10 (11%) 39 (15%) 0.3
Prior TIPS 41 (11%) 15 (16%) 26 (9.8%) 0.11
Intervention and CS 0 (0%) 0 (0%) 0 (NA%) >0.9
Coronary stenosis on catheterization 35 (9.7%) 35 (37%) 0 (0%) <0.001
Intervention 7 (7.4%) 7 (7.4%) 0 (NA%) >0.9
Positive non-invasive stress test 0 (0%) 0 (0%) 0 (0%) >0.9
CV complications post OLT - MACE 25 (7.0%) 5 (5.3%) 20 (7.5%) 0.5
Mortality only 9 (2.5%) 2 (2.1%) 7 (2.6%) >0.9
Mortality or MACE 26 (7.2%) 5 (5.3%) 21 (7.9%) 0.4
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

New table

T7 Mortality & MACE

Characteristic Overall, N = 4101 Mortality and MACE, N = 281 no Mortality and MACE, N = 3821 p-value2
Age, years 57 (50, 62) 57 (52, 62) 57 (50, 62) 0.8
Male 269 (66%) 15 (54%) 254 (66%) 0.2
Ethnicity 0.9
Caucasian 190 (46%) 13 (46%) 177 (46%)
Hispanic 116 (28%) 10 (36%) 106 (28%)
African American 60 (15%) 3 (11%) 57 (15%)
Asian 41 (10%) 2 (7.1%) 39 (10%)
Middle Eastern 3 (0.7%) 0 (0%) 3 (0.8%)
Family history of CAD 125 (30%) 6 (21%) 119 (31%) 0.3
Smoking history 207 (51%) 15 (54%) 192 (50%) 0.7
Hypertension 204 (50%) 13 (46%) 191 (50%) 0.7
Hyperlipidemia 62 (15%) 4 (14%) 58 (15%) >0.9
Diabetes mellitus 142 (35%) 13 (46%) 129 (34%) 0.2
Chronic kidney disease 95 (23%) 7 (25%) 88 (23%) 0.8
Connective tissue disease 12 (2.9%) 0 (0%) 12 (3.1%) >0.9
COPD 15 (3.7%) 1 (3.6%) 14 (3.7%) >0.9
Prior myocardial infarction 5 (1.2%) 0 (0%) 5 (1.3%) >0.9
Prior coronary artery disease 9 (2.2%) 0 (0%) 9 (2.4%) >0.9
Stroke 6 (1.5%) 0 (0%) 6 (1.6%) >0.9
HIV 4 (1.0%) 0 (0%) 4 (1.0%) >0.9
Cancer history 13 (3.2%) 1 (3.6%) 12 (3.1%) 0.6
Alcohol 125 (30%) 13 (46%) 112 (29%) 0.058
NASH 52 (13%) 4 (14%) 48 (13%) 0.8
Hepatitis B 33 (8.0%) 1 (3.6%) 32 (8.4%) 0.7
Hepatitis C 167 (41%) 10 (36%) 157 (41%) 0.6
Hepatocellular carcinoma 155 (38%) 7 (25%) 148 (39%) 0.15
Autoimmune hepatitis 32 (7.8%) 1 (3.6%) 31 (8.1%) 0.7
Cryptogenic 34 (8.3%) 3 (11%) 31 (8.1%) 0.7
Hepatobiliary disease 26 (6.3%) 1 (3.6%) 25 (6.5%) >0.9
Ascities 341 (83%) 26 (93%) 315 (82%) 0.2
Esophageal varices 243 (59%) 18 (64%) 225 (59%) 0.6
Hepatic encephalopathy 241 (59%) 22 (79%) 219 (57%) 0.028
Gastrointestinal bleed 115 (28%) 9 (32%) 106 (28%) 0.6
SBP 57 (14%) 7 (25%) 50 (13%) 0.090
Prior TIPS 52 (13%) 1 (3.6%) 51 (13%) 0.2
Coronary catheterization 0.2
0 277 (68%) 22 (79%) 255 (67%)
1 133 (32%) 6 (21%) 127 (33%)
Coronary stenosis on catheterization 0.4
0 361 (88%) 23 (82%) 338 (88%)
1 49 (12%) 5 (18%) 44 (12%)
Intervention 9 (6.8%) 0 (0%) 9 (7.1%) >0.9
Positive non-invasive stress test 0.5
0 359 (90%) 26 (96%) 333 (90%)
1 39 (9.8%) 1 (3.7%) 38 (10%)
CV complications post OLT - MACE 27 (6.6%) 27 (96%) 0 (0%) <0.001
Mortality only 9 (2.2%) 9 (32%) 0 (0%) <0.001
MELD-Na score at transplant 23 (19, 29) 26 (21, 32) 23 (19, 29) 0.11
1 Median (IQR); n (%)
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

T8 NEW TABLES AUGUST 2022

Characteristic Overall, N = 4101 Cardiac cath, N = 1331 No cardiac cath, N = 2771 p-value2
Mortality only 0.7
0 401 (98%) 131 (98%) 270 (97%)
1 9 (2.2%) 2 (1.5%) 7 (2.5%)
CV complications post OLT - HF 0.6
0 396 (97%) 130 (98%) 266 (96%)
1 14 (3.4%) 3 (2.3%) 11 (4.0%)
CV complications post OLT - MI >0.9
0 406 (99%) 132 (99%) 274 (99%)
1 3 (0.7%) 1 (0.8%) 2 (0.7%)
Unknown 1 0 1
Typer 1 MI >0.9
0 409 (100%) 133 (100%) 276 (100%)
1 1 (0.2%) 0 (0%) 1 (0.4%)
Typer 2 MI 0.5
0 408 (100%) 132 (99%) 276 (100%)
1 2 (0.5%) 1 (0.8%) 1 (0.4%)
CV complications post OLT - Stroke >0.9
0 409 (100%) 133 (100%) 276 (100%)
1 1 (0.2%) 0 (0%) 1 (0.4%)
CV complications post OLT - Card arrest 0.4
0 398 (97%) 131 (98%) 267 (96%)
1 12 (2.9%) 2 (1.5%) 10 (3.6%)
mortality_less_90_cath >0.9
0 132 (99%) 132 (99%) 0 (NA%)
1 1 (0.8%) 1 (0.8%) 0 (NA%)
Unknown 277 0 277
1 n (%)
2 Fisher's exact test
Characteristic Overall, N = 1331 No PCI, N = 1241 PCI, N = 91 p-value2
Mortality only >0.9
0 131 (98%) 122 (98%) 9 (100%)
1 2 (1.5%) 2 (1.6%) 0 (0%)
CV complications post OLT - HF >0.9
0 130 (98%) 121 (98%) 9 (100%)
1 3 (2.3%) 3 (2.4%) 0 (0%)
CV complications post OLT - MI >0.9
0 132 (99%) 123 (99%) 9 (100%)
1 1 (0.8%) 1 (0.8%) 0 (0%)
Typer 1 MI >0.9
0 133 (100%) 124 (100%) 9 (100%)
1 0 (0%) 0 (0%) 0 (0%)
Typer 2 MI >0.9
0 132 (99%) 123 (99%) 9 (100%)
1 1 (0.8%) 1 (0.8%) 0 (0%)
CV complications post OLT - Stroke >0.9
0 133 (100%) 124 (100%) 9 (100%)
1 0 (0%) 0 (0%) 0 (0%)
CV complications post OLT - Card arrest >0.9
0 131 (98%) 122 (98%) 9 (100%)
1 2 (1.5%) 2 (1.6%) 0 (0%)
mortality_less_90_cath >0.9
0 132 (99%) 123 (99%) 9 (100%)
1 1 (0.8%) 1 (0.8%) 0 (0%)
1 n (%)
2 Fisher's exact test
Characteristic Overall, N = 491 No PCI, N = 401 PCI, N = 91 p-value2
Mortality only >0.9
0 48 (98%) 39 (98%) 9 (100%)
1 1 (2.0%) 1 (2.5%) 0 (0%)
CV complications post OLT - HF >0.9
0 46 (94%) 37 (92%) 9 (100%)
1 3 (6.1%) 3 (7.5%) 0 (0%)
CV complications post OLT - MI >0.9
0 48 (98%) 39 (98%) 9 (100%)
1 1 (2.0%) 1 (2.5%) 0 (0%)
Typer 1 MI >0.9
0 49 (100%) 40 (100%) 9 (100%)
1 0 (0%) 0 (0%) 0 (0%)
Typer 2 MI >0.9
0 48 (98%) 39 (98%) 9 (100%)
1 1 (2.0%) 1 (2.5%) 0 (0%)
CV complications post OLT - Stroke >0.9
0 49 (100%) 40 (100%) 9 (100%)
1 0 (0%) 0 (0%) 0 (0%)
CV complications post OLT - Card arrest >0.9
0 48 (98%) 39 (98%) 9 (100%)
1 1 (2.0%) 1 (2.5%) 0 (0%)
mortality_less_90_cath >0.9
0 48 (98%) 39 (98%) 9 (100%)
1 1 (2.0%) 1 (2.5%) 0 (0%)
1 n (%)
2 Fisher's exact test

T9 NEW TABLE SEPTEMBER 2022

Characteristic Overall, N = 1331 No Stenosis, N = 841 Stenosis, N = 491 p-value2
Mortality only >0.9
0 131 (98%) 83 (99%) 48 (98%)
1 2 (1.5%) 1 (1.2%) 1 (2.0%)
CV complications post OLT - HF 0.048
0 130 (98%) 84 (100%) 46 (94%)
1 3 (2.3%) 0 (0%) 3 (6.1%)
CV complications post OLT - MI 0.4
0 132 (99%) 84 (100%) 48 (98%)
1 1 (0.8%) 0 (0%) 1 (2.0%)
Typer 1 MI >0.9
0 133 (100%) 84 (100%) 49 (100%)
1 0 (0%) 0 (0%) 0 (0%)
Typer 2 MI 0.4
0 132 (99%) 84 (100%) 48 (98%)
1 1 (0.8%) 0 (0%) 1 (2.0%)
CV complications post OLT - Stroke >0.9
0 133 (100%) 84 (100%) 49 (100%)
1 0 (0%) 0 (0%) 0 (0%)
CV complications post OLT - Card arrest >0.9
0 131 (98%) 83 (99%) 48 (98%)
1 2 (1.5%) 1 (1.2%) 1 (2.0%)
mortality_less_90_cath 0.4
0 132 (99%) 84 (100%) 48 (98%)
1 1 (0.8%) 0 (0%) 1 (2.0%)
CV complications post cath - MACE
0 133 (100%) 84 (100%) 49 (100%)
1 n (%)
2 Fisher's exact test